Fleury SA
BOVESPA:FLRY3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fleury SA
Common Stock
Fleury SA
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Fleury SA
BOVESPA:FLRY3
|
Common Stock
R$2.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
|
Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
|
Common Stock
R$4.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centro de Imagem Diagnosticos SA
BOVESPA:AALR3
|
Common Stock
R$1.1B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
D
|
Diagnosticos da America SA
BOVESPA:DASA3
|
Common Stock
R$19.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
24%
|
|
Fleury SA
Glance View
Fleury SA, originally founded in 1926, stands as a paragon of healthcare excellence in Brazil, evolving over nearly a century into a leading provider of medical diagnostics and integrated healthcare services. Driven by a culture of innovation and customer commitment, the company operates a network of strategically located diagnostic centers, offering a comprehensive array of tests, from basic blood work to sophisticated imaging. At the core of Fleury's operations is their ability to seamlessly blend cutting-edge technology with medical expertise, enabling them to deliver accurate diagnostics and personalized healthcare solutions. This approach not only enhances patient experiences but also fortifies their position in a highly competitive marketplace. In generating revenue, Fleury SA capitalizes on its robust infrastructure and premium service quality. The company’s business model thrives on a vast portfolio of diagnostic services, catering to an array of clientele — from individuals seeking routine checks to physicians requiring specialized analyses. Additionally, Fleury extends its reach through partnerships with hospitals and clinics, further solidifying its reputation and reliability. By maintaining a focus on operational efficiency and strategic expansions, the company ensures steady cash flows, which in turn are reinvested into technological advancements and service enhancements. This, coupled with their focus on high-quality client relations, fuels Fleury’s ability to retain a loyal customer base and sustain its financial growth trajectory.
See Also
What is Fleury SA's Common Stock?
Common Stock
2.7B
BRL
Based on the financial report for Dec 31, 2025, Fleury SA's Common Stock amounts to 2.7B BRL.
What is Fleury SA's Common Stock growth rate?
Common Stock CAGR 10Y
7%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Fleury SA have been 17% over the past three years , 14% over the past five years , and 7% over the past ten years .